ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 128 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $237,428 | -31.5% | 34,661 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $346,659 | +37.4% | 33,429 | +7.2% | 0.00% | 0.0% |
| Q1 2023 | $252,246 | -47.6% | 31,180 | +2.0% | 0.00% | -33.3% |
| Q4 2022 | $481,320 | -0.3% | 30,560 | -0.4% | 0.00% | -25.0% |
| Q3 2022 | $483,000 | +23.5% | 30,670 | +9.5% | 0.00% | +33.3% |
| Q2 2022 | $391,000 | -10.5% | 28,001 | +10.6% | 0.00% | +50.0% |
| Q1 2022 | $437,000 | +10.9% | 25,323 | -6.6% | 0.00% | 0.0% |
| Q4 2021 | $394,000 | -21.7% | 27,106 | -2.9% | 0.00% | -33.3% |
| Q3 2021 | $503,000 | +17.8% | 27,917 | +14.8% | 0.00% | +200.0% |
| Q2 2021 | $427,000 | +2147.4% | 24,328 | +33.4% | 0.00% | – |
| Q1 2020 | $19,000 | -47.2% | 18,241 | -5.5% | 0.00% | – |
| Q4 2019 | $36,000 | +71.4% | 19,294 | -0.8% | 0.00% | – |
| Q3 2019 | $21,000 | -51.2% | 19,457 | -0.7% | 0.00% | – |
| Q2 2019 | $43,000 | -68.1% | 19,592 | -13.2% | 0.00% | -100.0% |
| Q1 2019 | $135,000 | -21.5% | 22,576 | -3.1% | 0.00% | 0.0% |
| Q4 2018 | $172,000 | -33.1% | 23,307 | +31.4% | 0.00% | 0.0% |
| Q3 2018 | $257,000 | -26.1% | 17,732 | +1.8% | 0.00% | 0.0% |
| Q2 2018 | $348,000 | +33.8% | 17,414 | +17.2% | 0.00% | 0.0% |
| Q1 2018 | $260,000 | -32.6% | 14,860 | -5.1% | 0.00% | 0.0% |
| Q4 2017 | $386,000 | +10.6% | 15,659 | +15.9% | 0.00% | 0.0% |
| Q3 2017 | $349,000 | +2.9% | 13,512 | +8.1% | 0.00% | 0.0% |
| Q2 2017 | $339,000 | +67.0% | 12,502 | +83.7% | 0.00% | 0.0% |
| Q1 2017 | $203,000 | +44.0% | 6,804 | +31.3% | 0.00% | 0.0% |
| Q4 2016 | $141,000 | -99.9% | 5,181 | -0.3% | 0.00% | 0.0% |
| Q3 2016 | $133,044,000 | +38.8% | 5,195 | +0.1% | 0.00% | – |
| Q2 2016 | $95,822,000 | +52.1% | 5,188 | +56.2% | 0.00% | – |
| Q1 2016 | $63,000,000 | – | 3,321 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |